Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 11 2022
23 11 2022
Historique:
received:
21
06
2022
accepted:
14
11
2022
entrez:
23
11
2022
pubmed:
24
11
2022
medline:
26
11
2022
Statut:
epublish
Résumé
Cancer-associated fibroblasts (CAFs) play a significant role in tumor progression within the tumor microenvironment. Previously, we used near-infrared photoimmunotherapy (NIR-PIT), a next-generation cancer cell-targeted phototherapy, to establish CAF-targeted NIR-PIT. In this study, we investigated whether dual-targeted NIR-PIT, targeting cancer cells and CAFs, could be a therapeutic strategy. A total of 132 cases of esophageal cancer were analyzed for epidermal growth factor receptor (EGFR), human epidermal growth factor 2 (HER2), and fibroblast activation protein (FAP) expression using immunohistochemistry. Human esophageal cancer cells and CAFs were co-cultured and treated with single- or dual-targeted NIR-PIT in vitro. These cells were co-inoculated into BALB/c-nu/nu mice and the tumors were treated with single-targeted NIR-PIT or dual-targeted NIR-PIT in vivo. Survival analysis showed FAP- or EGFR-high patients had worse survival than patients with low expression of FAP or EGFR (log-rank, P < 0.001 and P = 0.074, respectively), while no difference was observed in HER2 status. In vitro, dual (EGFR/FAP)-targeted NIR-PIT induced specific therapeutic effects in cancer cells and CAFs along with suppressing tumor growth in vivo, whereas single-targeted NIR-PIT did not show any significance. Moreover, these experiments demonstrated that dual-targeted NIR-PIT could treat cancer cells and CAFs simultaneously with a single NIR light irradiation. We demonstrated the relationship between EGFR/FAP expression and prognosis of patients with esophageal cancer and the stronger therapeutic effect of dual-targeted NIR-PIT than single-targeted NIR-PIT in experimental models. Thus, dual-targeted NIR-PIT might be a promising therapeutic strategy for cancer treatment.
Identifiants
pubmed: 36418422
doi: 10.1038/s41598-022-24313-3
pii: 10.1038/s41598-022-24313-3
pmc: PMC9684531
doi:
Substances chimiques
Photosensitizing Agents
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20152Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20K09009
Informations de copyright
© 2022. The Author(s).
Références
Invest New Drugs. 2004 Jan;22(1):39-52
pubmed: 14707493
Onkologie. 2003 Feb;26(1):44-8
pubmed: 12624517
Gastroenterology. 2008 Jun;134(7):1981-93
pubmed: 18439605
World J Gastroenterol. 2013 Sep 14;19(34):5598-606
pubmed: 24039351
Nanoscale. 2016 Jul 7;8(25):12504-9
pubmed: 26443992
Breast Cancer Res. 2015 Nov 18;17:141
pubmed: 26581390
Theranostics. 2013 Apr 23;3(6):357-65
pubmed: 23781283
Cancer Biol Ther. 2007 Nov;6(11):1691-9
pubmed: 18032930
Int J Mol Sci. 2017 Jul 29;18(8):
pubmed: 28758931
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Sci Transl Med. 2016 Aug 17;8(352):352ra110
pubmed: 27535621
Int J Cancer. 2020 Feb 15;146(4):895-905
pubmed: 30734283
Gastric Cancer. 2020 Jan;23(1):82-94
pubmed: 31302791
Oncotarget. 2017 Nov 1;8(61):104295-104302
pubmed: 29262641
J Nucl Med. 2018 Sep;59(9):1423-1429
pubmed: 29626120
J Exp Med. 2013 Jun 3;210(6):1137-51
pubmed: 23712428
Mol Oncol. 2014 May;8(3):620-32
pubmed: 24508062
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Bioconjug Chem. 2012 Mar 21;23(3):604-9
pubmed: 22369484
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
J Cancer Res Clin Oncol. 2017 Nov;143(11):2351-2361
pubmed: 28756492
Lancet Oncol. 2013 Jun;14(7):627-37
pubmed: 23623280
Oncotarget. 2017 May 23;8(21):35069-35075
pubmed: 28456784
Nat Genet. 2015 Apr;47(4):320-9
pubmed: 25706628
Int J Cancer. 2019 Feb 15;144(4):828-840
pubmed: 30367467
Cancer Chemother Pharmacol. 2015 Dec;76(6):1113-32
pubmed: 26391154
JAMA Oncol. 2017 Nov 01;3(11):1520-1528
pubmed: 28687830
Nat Med. 2011 Nov 06;17(12):1685-91
pubmed: 22057348
BMC Cancer. 2016 Jan 25;16:37
pubmed: 26810644
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295
pubmed: 30778141
Cancer Biol Ther. 2019;20(9):1234-1248
pubmed: 31185791
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Oncogene. 2016 Oct 13;35(41):5337-5349
pubmed: 26923327
Pharm Res. 2019 Dec 23;37(1):12
pubmed: 31873819
Bioconjug Chem. 2019 Oct 16;30(10):2624-2633
pubmed: 31498995
Breast Cancer Res Treat. 2015 Feb;149(3):597-605
pubmed: 25616354
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):186-196
pubmed: 26278673
Nat Rev Clin Oncol. 2018 Jun;15(6):366-381
pubmed: 29651130
J Nucl Med. 2018 Sep;59(9):1412-1414
pubmed: 30097504
Cancer Immunol Res. 2020 Mar;8(3):345-355
pubmed: 31953245
ACS Cent Sci. 2018 Nov 28;4(11):1559-1569
pubmed: 30555909
Oncotarget. 2017 Jan 17;8(3):3933-3945
pubmed: 27965469
Oncotarget. 2017 Feb 7;8(6):10425-10436
pubmed: 28060726
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Sci Rep. 2021 Jan 18;11(1):1693
pubmed: 33462372
Esophagus. 2019 Jul;16(3):221-245
pubmed: 31098822
Clin Cancer Res. 2018 Oct 1;24(19):4820-4833
pubmed: 29921731
World J Gastroenterol. 2016 May 21;22(19):4619-25
pubmed: 27217694
N Engl J Med. 2014 Dec 25;371(26):2499-509
pubmed: 25539106
Gut. 2013 Jan;62(1):112-20
pubmed: 22466618
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978805
Gastric Cancer. 2019 May;22(3):463-472
pubmed: 30171392
Ann Thorac Cardiovasc Surg. 2012;18(6):506-13
pubmed: 23232268
Nihon Hoshasen Gijutsu Gakkai Zasshi. 2017;73(5):397-402
pubmed: 28529254
Clin Cancer Res. 2003 May;9(5):1639-47
pubmed: 12738716